FANJ
ADMS

Financial Architects (New Jersey)’s Adamas Pharmaceuticals ADMS Stock Holding History

Financial Architects (New Jersey)’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,000
Closed -$52K – 1013
2015
Q2 		$52K Buy
+2,000
New +$38.9K 0.02% 429

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Financial Architects (New Jersey)'s ADMS Position: Q3 2015 in Review

Financial Architects (New Jersey) sold out of Adamas Pharmaceuticals (ADMS) in Q3 2015, closing a stake of 2,000 shares — an estimated $52K sold.

Financial Architects (New Jersey) first reported a position in ADMS in Q2 2015 and held it in 1 quarter. The position peaked at $52K in Q2 2015. 83 funds tracked by Wall St. Rank hold ADMS as of Q3 2015.

  • Financial Architects (New Jersey) reported no remaining Adamas Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 2,000 Adamas Pharmaceuticals shares in Q3 2015, an estimated $52K.
  • Financial Architects (New Jersey) first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Adamas Pharmaceuticals position peaked at $52K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2015.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2015, filed 13 Nov 2015.